SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (PRCT) ® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative ...

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by ...

Truist lowered the firm’s price target on Procept BioRobotics (PRCT) to $30 from $47 but keeps a Buy rating on the shares. The company’s Q4 missed estimates, though its Analyst Day laid out a case for ...

PROCEPT BioRobotics Corporation (PRCT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM ESTCompany ParticipantsLarry Wood - President, ...

The contraction process involves interactions between actin and myosin filaments within the sarcomeres to generate force. Recent research has achieved significant advances in functional design, ...

Procept is a medical technology company offering a surgical procedure for benign prostatic hyperplasia (“BPH”), the enlargement of the prostate as a man ages, which can disrupt or block the urethra ...

Director Antal Rohit Desai of PROCEPT BioRobotics Corp (NASDAQ:PRCT) reported purchasing shares of common stock in multiple transactions between March 5 and March 9, 2026. The total value of these ...

The market expects PROCEPT BioRobotics Corporation (PRCT) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2025. This ...